bioAffinity Technologies

bioAffinity Technologies Addressing the need for noninvasive diagnosis of early-stage cancer and targeted cancer treatment. www.cypathlung.com

Our flagship product, CyPath® Lung, is a noninvasive early lung cancer diagnostic.

04/24/2026

Pulmonary nodules are most often benign, but sometimes waiting for the next scan risks missing a critical early-stage cancer.

CyPath® Lung helps clinicians detect early-stage lung cancer, providing actionable results that can prompt timely intervention. Catching lung cancer at curative Stage 1 can make a significant difference in outcomes and patient care.

Learn more: https://www.cypathlung.com/

This Administrative Professionals Day, we celebrate the dedicated administrative professionals at bioAffinity Technologi...
04/22/2026

This Administrative Professionals Day, we celebrate the dedicated administrative professionals at bioAffinity Technologies, Precision Pathology Laboratory Services, and in the offices of our physician partners. Your work makes it possible to deliver innovations like CyPath® Lung to the patients who need them. We’re grateful for all that you do.

04/22/2026

Pulmonary nodules can create anxiety for patients, especially when it’s unclear whether intervention is needed.

CyPath® Lung gives clinicians insight into malignancy risk, helping to identify when invasive procedures are called for or when results show that watchful waiting is more appropriate. This additional information can provide patients with peace of mind while supporting more informed discussions.

Learn more: https://www.cypathlung.com/

We’re proud to recognize the experts behind the scenes who make precision within the lab possible.At Precision Pathology...
04/21/2026

We’re proud to recognize the experts behind the scenes who make precision within the lab possible.

At Precision Pathology, our team leads with accuracy, innovation, and care. Their work is essential to advancing diagnostics and improving outcomes for patients and providers.

Thank you to our laboratory professionals for your continued commitment to excellence and the impact you make across the healthcare system.

Cancer touches nearly every family.That’s why innovations like CyPath® Lung matter. By offering a noninvasive way to ass...
04/17/2026

Cancer touches nearly every family.

That’s why innovations like CyPath® Lung matter. By offering a noninvasive way to assess lung nodules and cancer risk, CyPath Lung is helping clinicians detect disease earlier, reduce unnecessary invasive procedures, and guide more informed care decisions.

Early detection saves lives. This month—and every month—is an opportunity to raise awareness, encourage screenings, and support those facing cancer today while celebrating survivors everywhere.

04/17/2026

For older patients or those with comorbidities, avoiding unnecessary invasive procedures can be critical.

CyPath® Lung helps clinicians evaluate pulmonary nodules and stratify malignancy risk, giving care teams the greater confidence to perform procedures. Patients are assured when invasive procedures are called for or less anxious when results show that “watchful waiting” is more appropriate.

Learn more: https://www.cypathlung.com/

CyPath® Lung was part of an important conversation at the Cleveland Clinic today when Dr. Gordon Downie participated in ...
04/16/2026

CyPath® Lung was part of an important conversation at the Cleveland Clinic today when Dr. Gordon Downie participated in a panel to discuss the evolving landscape of pulmonary lung nodule management.

As incidental nodules continue to rise with increased imaging, the need for accurate, noninvasive tools to guide clinical decision-making has never been greater. Conversations like these highlight the critical role of innovation in helping physicians better stratify risk and avoid unnecessary invasive procedures.

Coverage from Clinical Lab Products : CyPath® Lung is gaining traction in clinical practice, with unit sales increasing ...
04/16/2026

Coverage from Clinical Lab Products : CyPath® Lung is gaining traction in clinical practice, with unit sales increasing 146% in the first quarter of 2026.

The noninvasive diagnostic provides a binary result of “likely” or “unlikely” malignancy to support clinical decision-making and help physicians manage patients with indeterminate pulmonary nodules.

Read more: https://bit.ly/4233QO9

04/15/2026

In interventional pulmonology, knowing which nodules warrant more aggressive follow-up is important.

CyPath® Lung helps clinicians risk-stratify patients, providing insight into malignancy risk before invasive steps are taken.

CyPath® Lung can help with shared decision-making, assuring a patient when invasive procedures are called for or watchful waiting is more appropriate. Learn more: https://www.cypathlung.com/

A new case study from bioAffinity Technologies highlights a high-risk patient with a suspicious 30-mm nodule and elevate...
04/14/2026

A new case study from bioAffinity Technologies highlights a high-risk patient with a suspicious 30-mm nodule and elevated predicted risk scores who was scheduled for biopsy. Her physician routinely uses our noninvasive CyPath® Lung test in his practice and ordered the test prior to the invasive procedure.

A result of “Unlikely Malignancy,” later confirmed by resolution of the nodule on follow-up imaging, spared the patient from an unnecessary invasive procedure that would have posed additional risk given her comorbidities, including emphysema.

Read the full case study: https://bit.ly/3OFT5yi

ICYMI: CyPath® Lung is returning to the Cleveland Clinic’s annual “Advances in Early Lung Cancer Detection” symposium on...
04/13/2026

ICYMI: CyPath® Lung is returning to the Cleveland Clinic’s annual “Advances in Early Lung Cancer Detection” symposium on April 16, joining global leaders focused on improving how lung cancer is identified at its earliest and most treatable stages.

BioAffinity Technologies Chief Medical Officer Gordon Downie, MD, PhD, will be one of three panelists discussing lung nodule management, highlighting the benefits of using CyPath® Lung to assess risk and detect early-stage lung cancer in high-risk patients.

Learn more: https://bit.ly/4cAN4fq

04/10/2026

When evaluating pulmonary nodules, timely information can make a meaningful difference for both clinicians and patients.

CyPath® Lung provides actionable results with efficient turnaround times, helping care teams respond to patient concerns and move forward with patient care. Timely diagnostic insight supports more informed next steps. Learn more: https://www.cypathlung.com/

Address

3300 Nacogdoches Road Ste 216
San Antonio, TX
78217

Telephone

+12106985334

Website

Alerts

Be the first to know and let us send you an email when bioAffinity Technologies posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Share